drugset / Trial / NCT02667704

Influence of Bosentan on the Pharmacokinetics of Nintedanib

NCT02667704

Phase 1 Completed 13 enrolled Boehringer Ingelheim
Non-randomizedCrossoverOpen-labelTreatment

Summary

The trial was designed to investigate whether, and to which extent, multiple doses of bosentan may influence the plasma levels of nintedanib administered as a single dose.

Timeline

Start
2016-02
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified
Subject Nintedanib Small molecule

Indications

No indication recorded.